PT -期刊文章盟-埃里克·r·Kimmel盟萨米艾尔卡萨伯AU - Girish Bathla盟吉莉安·哈维AU -圣地亚哥奥尔特加古铁雷斯盟Kaustubh Limaye AU -安琼斯Van De机器人瓦力盟恩里克·c·Leira AU -大卫·m·哈桑盟埃德加·a·萨马尼TI -没有络脉与大梗死体积和糟糕的结果(p5.3 - 047) DP - 2019年4月09年TA -神经病学第六PG - p5.3 - 047 - 92 IP - 15补充4099 - //www.ez-admanager.com/content/92/15_supplement/p5.3 047. - 047.短4100 - //www.ez-admanager.com/content/92/15_supplement/p5.3 - -全所以Neurol首页ogy2019 4月09年;92 AB -目的:评估抵押物的使用评分在预测临床结果和最终LVO轻微症状患者的梗死体积。背景:最近的试验已经证明机械血栓切除术的有效性(MT)前循环患者大血管闭塞(LVO)和严重的中风症状,然而鲜为人知的最佳治疗患者LVO和轻微的症状。设计/方法:回顾性研究的前瞻性收集的数据与轻度缺血性中风患者(署& lt;6)与LVO 09/2015和07/2017。收集的数据包括人口、入学署方面,闭塞的位置,间接得分,最终梗塞体积,90天的夫人的分数。病人太被排除在我们的分析。负二项分布的广义线性回归模型,一个日志链接以及广义线性回归模型用于这些分析。结果:41例。平均年龄为67.8岁,92.7%是白人,56.1%是男性。入学署中位数为3。最常见的血管是涉及MCA (63.3%, M2 = 34.7%), ICA(34.7%),和ACA (2%)。 Twelve patients received tPA. Mean ASPECTS was 9, mean collateral score was 2. Mean infarct volume was 18.6 mL. A good functional outcome (mRS 0–2) at 90 days was achieved in 81 % of patients. A spearman Rho correlation coefficient was used to evaluate the relationship between collateral score and final infarct volume. There was a negative relationship between collateral score and final infarct volume (−0.3134, P=0.046). Logistic regression showed that with a one-point increase in admission NIHSS there was a 22% higher chance of a 4mL increase in final infarct volume. Higher infarct volume was associated with lower odds of achieving good functional outcome (mRS 0–2) (RR 0.99, P=0.022 [95% CI 0-978–0.98]).Conclusions: The absence of collaterals correlates with a larger final infarct volume and a worse long-term functional outcome.Disclosure: Dr. Kimmel has nothing to disclose. Dr. Alkasab has nothing to disclose. Dr. Bathla has nothing to disclose. Dr. Harvey has nothing to disclose. Dr. Ortega Gutierrez has nothing to disclose. Dr. Limaye has nothing to disclose. Dr. Van De Walle Jones has nothing to disclose. Dr. Leira has nothing to disclose. Dr. Hasan has nothing to disclose. Dr. Samaniego has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Microvention/Medtronic.

map